PSA
48
2
HD
35
-11
HST
39
-5
REGN
65
2
SRE
61
14
APA
30
5
EMC
85
38
SYF
83
2
BLK
69
11
AZO
45
2
COP
47
2
RCL
62
-3
AFL
66
2
QRVO
34
-4
BWA
61
-7
CAH
43
2
CTSH
49
-2
UNM
70
2
EXC
58
11
ABBV
64
4
PSA
48
2
HD
35
-11
HST
39
-5
REGN
65
2
SRE
61
14
APA
30
5
EMC
85
38
SYF
83
2
BLK
69
11
AZO
45
2
COP
47
2
RCL
62
-3
AFL
66
2
QRVO
34
-4
BWA
61
-7
CAH
43
2
CTSH
49
-2
UNM
70
2
EXC
58
11
ABBV
64
4
Financhill
Back

LENZ Therapeutics Quote, Financials, Valuation and Earnings

Buy
100

LENZ
LENZ Therapeutics

Last Price:
16.36
Seasonality Move:
--

7 Day Trial

ALL ACCESS PASS

$ 7

LENZ Therapeutics Price Quote

$16.36
+0.01 (+-1.03%)
(Updated: May 18, 2024 at 5:47 AM ET)

LENZ Therapeutics Key Stats

Buy
100
LENZ Therapeutics (LENZ) is a Buy
Day range:
$16.21 - $17.25
52-week range:
$15.00 - $24.59
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
2.11%
Volume:
168.9K
Avg. volume:
149K
1-year change:
0%
Market cap:
$417.5M
Revenue:
$15M
EPS:
$-5.32

How Much Does LENZ Therapeutics Make?

Data Unavailable

Is LENZ Therapeutics Growing As A Company?

Data Unavailable

LENZ Therapeutics Stock Price Performance

What Is LENZ Therapeutics 52-Week High & Low?

LENZ Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy LENZ Therapeutics?

  • How Much Debt Does LENZ Therapeutics Have?
    Total long term debt quarterly is $0
  • How Much Cash Does LENZ Therapeutics Have?
    Cash and short term investments quarterly total is $213.3M
  • What Is LENZ Therapeutics’s Book Value Per Share?
    Book value per share is 7.77

Is LENZ Therapeutics Cash Flow Positive?

Data Unavailable

LENZ Therapeutics Return On Invested Capital

Data Unavailable

LENZ Therapeutics Earnings Date & Stock Price

LENZ Therapeutics Competitors

  • Who Are LENZ Therapeutics's Competitors?
    Below is a list of companies who compete with LENZ Therapeutics or are related in some way:
    • MoonLake Immunotherapeutics (MLTX)
    • PetMed Express Inc (PETS)
    • R1 RCM Inc (RCM)
    • Streamline Health Solutions Inc (STRM)
    • TruBridge Inc (TBRG)

LENZ Therapeutics Dividend Yield

Data Unavailable

LENZ Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 0%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 3
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 36.75
Upside from Last Price: 124.77%

Major Shareholders

  • How many LENZ shares are owned by institutional investors?
    14M LENZ shares are owned by institutional investors
  • How many LENZ shares are owned by insiders?
    194.6K LENZ shares are owned by insiders